LEXX — what changed in the latest 10-Q
A section-by-section comparison of LEXX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-13 vs the prior 10-Q · 2026-04-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +8 | −11 | ~27 | 28 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No paragraph-level changes | 0 | 0 | 0 | 9 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-13
Announced information on three new studies from its 2026 R&D Program, including the receipt of ethics board approval for its Human Pilot Study #7 (GLP-1-H26-7), the engagement of the contract research organization for each of its two GLP-1 animal studies, Animal Study #1 (GLP-1-A26-1) and Animal Stu…
During the quarter ended May 31, 2026, Lexaria engaged its contract research organization (“CRO”) and received ethics board approval for this 5-week parallel group design study intended to evaluate the safety, tolerability and pharmacokinetic (“PK”) properties of two oral DehydraTECH-semaglutide com…
A DehydraTECH-semaglutide tablet formulated to mimic Novo Nordisk’s® Rybelsus® and Wegovy® oral semaglutide tablets which incorporate salcaprozate sodium (“SNAC”) and are designed to temporarily adhere to the stomach lining and disintegrate and dissolve releasing agents in a focal manner that aids i…
A DehydraTECH-semaglutide capsule, as previously investigated by Lexaria (AU) Pty Ltd in our Phase 1b clinical trial (GLP-1-H24-4) performed in Australia, but with the addition of SNAC as was also the case in our previous successful clinical study GLP-1-H24-1.
Results from this study are anticipated to be released during the second quarter of fiscal year 2027.
Text removed vs the prior filing · source: 10-Q · 2026-04-13
Announced information on three new studies from its 2026 R&D Program which are representative of the Company’s primary areas of focus during for the fiscal year (see MD&A Research & Development section below).
During the quarter ended February 28, 2026, Lexaria via its wholly owned subsidiary, Lexaria (AU) Pty Ltd, completed the close-out and data analysis activities for its Australian clinical study (GLP-1-H24-4), with its CRO service provider, Novotech (Australia) Pty Limited. GLP-1-H24-4 investigated D…
Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible for the Australian research and development incentive described in Note 2 above and has submitted an application for the credit with res…
During the quarter ended February 28, 2026, Lexaria with its third-party bioanalytical service providers completed its pharmacokinetic (“PK”) blood liraglutide quantitation and profiling results from this study. This included the use of two different manufactured brands of commercially available ELI…
The two most important strategic objectives of this study were:
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice